Laigo Bio
Utrecht
About Laigo Bio
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $19.8M
- Funding stage: Seed
- Last round: Seed (Mar 2026)
- Website: laigobio.comen
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/laigo-bio-41225 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.